Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06164236

Acronym

NALAPOST

Enrollment

300

Registered

2023-12-11

Start date

2020-10-19

Completion date

2024-04-19

Last updated

2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Keywords

Postpartum haemorrhage, Maternal morbidity, Oxytocin, Sulprostone, Uterine Hemorrhage, Obstetric Labor Complications

Brief summary

The investigators wish to identify potential factors predicting failure of second-line drug treatment (sulproston (Nalador®)): risk factors and factors linked to a failure to take initial care for PPH. A better understanding of the aggravating factors of HPP and more particularly the factors inherent to the initial care would make it possible to think of ways to improve practices.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major subject (≥18 years old) * Subject having given birth at HUS or CHU Poissy Saint-Germain-en Laye between 01/01/2019 and 31/12/2020 * Subject having presented a postpartum haemorrhage treated with Sulprostone * Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research

Exclusion criteria

* Subject having expressed opposition to participating in the study * Subject under guardianship or guardianship * Subject under safeguard of justice

Design outcomes

Primary

Measure	Time frame
This a rétrospective study trayning to identify a potential predictors of failure of second-line drug treatment in the case of severe postpartum hemorrhage	1 year

Countries

France

Outcome results